Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention

Journal of Korean Neurosurgical Society

Volumn 48, Issue 4, 2010, Pages 319-324

  Ryu, Dal Sung ^a   Hong, Chang Ki ^a   Sim, Yoo Sik ^a   Kim, Chang Hyun ^a   Joo, Jin Young ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Aspirin; Clopidogrel; Neurointervention; Resistance

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR DISEASE; COIL EMBOLIZATION; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INTRACRANIAL ANEURYSM; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; STENT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM;

EID: 78549231969     PISSN: 20053711     EISSN: 15987876     Source Type: Journal    
DOI: 10.3340/jkns.2010.48.4.319     Document Type: Article

References (35)

1. Albers GW: Antithrombotic agents in cerebral ischemia. Am J Cardiol 75: 34B-38B, 1995
2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabate M, Jimenez-Quevedo P, et al.: Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54: 2430-2435, 2005
3. Cairns JA, Eikelboom J: Clopidogrel resistance: more grist for the mill. J Am Coll Cardiol 51: 1935-1937, 2008
4. Cattaneo M: Laboratory detection of 'aspirin resistance': what test should we use (if any)? Eur Heart J 28: 1673-1675, 2007
5. Coma-Canella I, Valasc A: Variability in individual responsiveness to aspirin: clinical implications and treatment. Cardiovasc Haematol Disord Drug Targets 7: 274-287, 2007
6. Csiszar A, Stef G, Pacher P, Ungvari Z: Oxidative stress-induced iso-prostane formation may contribute to aspirin resistance in platelets. Pro-staglandins Leukot Essent Fatty Acids 66: 557-558, 2002
7. Dalen JE: Aspirin resistance: is it real? Is it clinically significant? Am J Med 120: 1-4, 2007
8. Davi G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, et al.: Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 96: 69-75, 1997
9. Ferreira IA, Mocking AI, Feijge MA, Gorter G, van Haeften TW, Heemskerk JW, et al.: Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 26: 417-422, 2006
10. Fitzgerald DJ, Maree A: Aspirin and clopidogrel resistance. Hemato-logy Am Soc Hematol Educ Program: 114-120, 2007
11. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A: Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 34: 849-854, 2003
12. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US: The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coro-nary stenting. J Am Coll Cardiol 45: 1392-1396, 2005
13. Gurbel PA, Tantry US: Clopidogrel resistance? Thromb Res 120: 311-321, 2007
14. Lee DH, Arat A, Morsi H, Shaltoni H, Harris JR, Mawad ME: Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. AJNR Am J Neuroradiol 29: 1389-1394, 2008
15. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, et al.: Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 46: 1833-1837, 2005
16. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, et al.: Aspirin and clopidogrel drug response in patients undergoing per-cutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47: 27-33, 2006
17. Li Y, Woo V, Bose R: Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 280: H1480-1489, 2001
18. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary inter-vention: the PCI-CURE study. Lancet 358: 527-533, 2001
19. Motovska Z, Widimsky P, Petr R, Bilkova D, Marinov I, Simek S, et al.: Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary inter-vention: statin's advantage and the smoking "paradox". J Cardiovasc Pharmacol 53: 368-372, 2009
20. Oqueli E, Hiscock M, Dick R: Clopidogrel resistance. Heart Lung Circ 16 Suppl 3: S17-S28, 2007
21. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Char-bonnier B, et al.: Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiol-ogy. Eur Heart J 25: 166-181, 2004
22. Prabhakaran S, Wells KR, Lee VH, Flaherty CA, Lopes DK: Preval-ence and risk factors for aspirin and clopidogrel resistance in cerebrova-scular stenting. AJNR Am J Neuroradiol 29: 281-285, 2008
23. Rothrock JF, Hart RG: Antithrombotic therapy in cerebrovascular disease. Ann Intern Med 115: 885-895, 1991
24. Saratzis A, Saratzis N, Melas N, Kiskinis D: Pharmacotherapy before and after endovascular repair of abdominal aortic aneurysms. Curr Vasc Pharmacol 6: 240-249, 2008
25. Shim CY, Yoon SJ, Park S, Kim JS, Choi JR, Ko YG, et al.: The clopi-dogrel resistance can be attenuated with triple antiplatelet therapy in pati-ents undergoing drug-eluting stents implantation. Int J Cardiol 134: 351-355, 2009
26. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288: 2411-2420, 2002
27. Szczeklik A, Musial J, Undas A, Gajewski P, Góra P, Swadzba J, et al.: Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 33: 1286-1293, 1999
28. Tschoepe D, Roesen P, Esser J, Schwippert B, Nieuwenhuis HK, Kehrel B, et al.: Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 17: 433-438, 1991
29. von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I, et al.: A double-blind, randomized study on platelet aggre- gation in patients treated with a daily dose of 150 or 75 mg of clopido- grel for 30 days. Eur Heart J 28: 1814-1819, 2007
30. Wang TH, Bhatt DL, Topol EJ: Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27: 647-654, 2006
31. Weksler BB, Lewin M: Anticoagulation in cerebral ischemia. Stroke 14: 658-663, 1983
32. Winocour PD, Watala C, Perry DW, Kinlough-Rathbone RL: Dec-reased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost 68: 577-582, 1992
33. Wiviott SD: Clopidogrel response variability, resistance, or both? Am J Cardiol 98: 18N-24N, 2006
34. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015, 2007
35. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494-502, 2001